Overall Survival Results for Kyprolis ASPIRE Myeloma Study Released
Kyprolis (carfizomib) is a proteasome inhibitor that is is FDA approved to be used in myeloma treatment combinations based on study results of the ASPIRE trial, which evaluated Kyprolis, lenalidomide and dex vs. lenalidomide and dex alone. The study began years ago and recruited almost 800 patients from July 2010 - March 2012. Recent ASPIRE results posted today in the Journal of Clinical Oncology showed that adding Kyprolis to Revlimid and dex (KRd) reduced the risk of death by 21 percent compared to lenalidomide and dexamethasone (Rd) alone. Median overall survival was 48.3 months for KRd compared to 40.4 months for Rd. An overall survival improvement of 11.4 months was observed for patients at first relapse. Patients using KRd relapsed at 47.3 months while Rd patients relapsed at 35.9 months. Principal investigator Keith Stewart, M.B., Ch.B., Mayo Clinic in Arizona said:
"Results from the final analysis of the Phase 3 ASPIRE trial published today in the Journal of Clinical Oncology are significant, as they further validate carfilzomib, lenalidomide and dexamethasone as a standard of care regimen for patients with relapsed or refractory multiple myeloma. Furthermore, these data showed that early use of carfilzomib, lenalidomide and dexamethasone at first relapse provided nearly one additional year of survival for patients regardless of prior treatment with bortezomib or transplant."
The Kyprolis, Revlimid, dex combination is currently FDA approved in the US, European Union and other countries based on prior ASPIRE results.